144 related articles for article (PubMed ID: 12354135)
1. Preparation for radioactive iodine administration in differentiated thyroid cancer patients.
Liel Y
Clin Endocrinol (Oxf); 2002 Oct; 57(4):523-7. PubMed ID: 12354135
[TBL] [Abstract][Full Text] [Related]
2. Plasmapheresis rapidly eliminates thyroid hormones from the circulation, but does not affect the speed of TSH recovery following prolonged suppression.
Liel Y; Weksler N
Horm Res; 2003; 60(5):252-4. PubMed ID: 14614231
[TBL] [Abstract][Full Text] [Related]
3. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer.
Serhal DI; Nasrallah MP; Arafah BM
J Clin Endocrinol Metab; 2004 Jul; 89(7):3285-9. PubMed ID: 15240604
[TBL] [Abstract][Full Text] [Related]
4. Liquid liothyronine to obtain target TSH in differentiated thyroid cancer patients.
Trimboli P; Centanni M; Virili C
Endocr J; 2016 Jun; 63(6):563-7. PubMed ID: 27000530
[TBL] [Abstract][Full Text] [Related]
5. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning.
Chow SM; Au KH; Choy TS; Lee SH; Yeung NY; Leung A; Leung A; Leung HL; Shek CC; Law SC
Laryngoscope; 2006 Nov; 116(11):2060-6. PubMed ID: 17075410
[TBL] [Abstract][Full Text] [Related]
7. Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal.
Kuijt WJ; Huang SA
J Clin Endocrinol Metab; 2005 Nov; 90(11):6123-5. PubMed ID: 16091480
[TBL] [Abstract][Full Text] [Related]
8. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer.
Iorcansky S; Herzovich V; Qualey RR; Tuttle RM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6553-5. PubMed ID: 16174712
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
10. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine.
Edmonds CJ; Hayes S; Kermode JC; Thompson BD
Br J Radiol; 1977 Nov; 50(599):799-807. PubMed ID: 588901
[TBL] [Abstract][Full Text] [Related]
11. Comparison of conventional L-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing.
Marturano I; Russo M; Spadaro A; Latina A; Malandrino P; Regalbuto C
J Endocrinol Invest; 2015 Sep; 38(9):1017-22. PubMed ID: 26070652
[TBL] [Abstract][Full Text] [Related]
12. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments.
Grani G; Tumino D; Ramundo V; Ciotti L; Lomonaco C; Armillotta M; Falcone R; Lucia P; Maranghi M; Filetti S; Durante C
J Endocrinol Invest; 2019 Dec; 42(12):1485-1490. PubMed ID: 31203497
[TBL] [Abstract][Full Text] [Related]
13. Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma.
Olveira G; Almaraz MC; Soriguer F; Garriga MJ; Gonzalez-Romero S; Tinahones F; Ruiz de Adana MS
Clin Endocrinol (Oxf); 1997 Jun; 46(6):707-11. PubMed ID: 9274701
[TBL] [Abstract][Full Text] [Related]
14. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
15. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer.
Burmeister LA; Goumaz MO; Mariash CN; Oppenheimer JH
J Clin Endocrinol Metab; 1992 Aug; 75(2):344-50. PubMed ID: 1639933
[TBL] [Abstract][Full Text] [Related]
16. TSH suppression by octreotide in differentiated thyroid carcinoma.
Maini CL; Sciuto R; Tofani A
Clin Endocrinol (Oxf); 1994 Mar; 40(3):335-9. PubMed ID: 8187297
[TBL] [Abstract][Full Text] [Related]
17. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
18. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
19. Timing of Hormone Withdrawal in Children Undergoing 131I Whole-Body Scans for Thyroid Cancer.
Turpin S; Lambert R; Deal C
Horm Res Paediatr; 2016; 86(6):410-415. PubMed ID: 27902975
[TBL] [Abstract][Full Text] [Related]
20. Effect of thyrotropin suppressive therapy on heart rate variability and QT dispersion in patients with differentiated thyroid cancer.
Liu C; Lv H; Li Q; Fu S; Tan J; Wang C; Wang X; Ma Y
Medicine (Baltimore); 2020 Jul; 99(28):e21190. PubMed ID: 32664162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
